Related Experiment Videos
[Editorial: Hepatic control of the metabolism of thyroid hormones]
Acta Gastro-Enterologica Belgica
|July 1, 1973
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Pharmacokinetics and safety of single oral doses of amlodipine in patients with and without hepatic impairment: an open study.
International journal of clinical pharmacology research·1993
[Current etiological problems, in France, posed by primary liver cancer after cirrhosis. Personal observations of 130 cases].
Annales de gastroenterologie et d'hepatologie·1991
[Current etiological problems, in France, related to primary liver cancer in cirrhosis (personal observation of 130 cases)].
Bulletin de l'Academie nationale de medecine·1991
Rioprostil in the short-term treatment of duodenal ulcer: a multicentre double-blind trial vs. cimetidine.
Scandinavian journal of gastroenterology. Supplement·1989
Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis.
Hepatology (Baltimore, Md.)·1987
Silent Fungus, Sudden Crisis: Gastrointestinal Bleeding due to Disseminated Histoplasmosis.
Acta gastro-enterologica Belgica·2026
Acute oesophageal necrosis following ethyl-induced emesis: A Case Report.
Acta gastro-enterologica Belgica·2026
Conservative Management of Omental Infarction Using Only Analgesia.
Acta gastro-enterologica Belgica·2026
Angor abdominalis caused by a pancreatic arteriovenous malformation: a case report.
Acta gastro-enterologica Belgica·2026
Gastric Trichobezoars in Children and Adolescents: A Single-Center Case Series.
Acta gastro-enterologica Belgica·2026
Proteolytic remodeling by Yme1 enables mitochondrial-derived compartment formation.
bioRxiv : the preprint server for biology·2026
Oxidative Stress as a Pathophysiological Core of Obesity: Preclinical Evidence for Antioxidant-Based Therapy Strategies.
Pharmaceuticals (Basel, Switzerland)·2026
Flavonoids for MASLD: Hepatic Lipid Targets, Biopharmaceutic Barriers, and Formulation Strategies.
Pharmaceuticals (Basel, Switzerland)·2026